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Background
Human cancer cells may suppress the adaptive immune
response by expressing PD-L1 and down-regulating
T cell activity through PD-L1/PD-1 and PD-L1/B7.1
interactions. Disruption of PD-L1 signaling restores anti-
tumor immunity, resulting in durable responses across
multiple human tumor types. Here we describe the clini-
cal activity and development of predictive biomarkers for
MPDL3280A, a human monoclonal antibody with an
engineered Fc-domain designed to optimize safety and
efficacy, that targets PD-L1 and prevents binding to
receptors PD-1 and B7.1.
Materials & methods
We evaluated a multitude of biomarkers from pretreat-
ment tumor specimens collected during clinical study of
MPDL3280A. MPDL3280A has been administered as a
monotherapy in over 300 pts with locally advanced or
metastatic solid tumors in a phase 1 study.
Results
To date, MPDL3280A has been well tolerated across
multiple dose levels and no G3-5 pneumonitis has been
reported. Responses were observed in multiple tumor
types, including NSCLC, RCC, and melanoma, with
ongoing responses seen in the majority of responders.
We report the association between pretreatment
immune-related markers and response to MPDL3280A.
Conclusion
Overall, our assessment of tumor specimens not only
has resulted in markers that may potentially identify
response to MPDL3280A but also has furthered our
understanding of the biologic activity of PD-L1 inhibi-
tion on treatment.
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